Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP) chief operating officer Clarissa Sowemimo-Coker joined Proactive's Stephen Gunnion with details of a drug development agreement with Oxford StemTech, the custom cell reprogramming specialist.
The contract research group will provide support for OCT’s drug development efforts, starting with programmes three and four, targeting pain, neurology and inflammation.
Using cell technology pioneered by Professor Zameel Cader and his team, Sowemimo-Coker said the aim is to predict in the lab human responses to OCT’s cannabinoid-based treatments using re-engineered stem cells.